ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin

Am J Hematol. 2012 Jan;87(1):116-9. doi: 10.1002/ajh.22185. Epub 2011 Oct 12.

Authors

Muneo Ohshiro¹, Junya Kuroda, Yutaka Kobayashi, Teruaki Akaogi, Eri Kawata, Nobuhiko Uoshima, Yuri Kamitsuji, Hiroto Kaneko, Kazuho Shimura, Chihiro Shimazaki, Satoshi Murakami, Mayumi Hatsuse, Akira Okano, Tsutomu Kobayashi, Hitoji Uchiyama, Yosuke Matsumoto, Shigeo Horiike, Masafumi Taniwaki

Affiliation

¹ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

PMID: 21989545
DOI: 10.1002/ajh.22185

No abstract available

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

ADAM Proteins / metabolism*
ADAMTS13 Protein
Biomarkers / metabolism
Disseminated Intravascular Coagulation / diagnosis
Disseminated Intravascular Coagulation / drug therapy*
Disseminated Intravascular Coagulation / etiology
Disseminated Intravascular Coagulation / mortality
Hematologic Neoplasms / complications*
Humans
Kaplan-Meier Estimate
Prognosis
Prospective Studies
Recombinant Proteins / therapeutic use
Thrombomodulin / therapeutic use*

Substances

Biomarkers
Recombinant Proteins
Thrombomodulin
ADAM Proteins
ADAMTS13 Protein
ADAMTS13 protein, human